Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPL026 + selective serotonin reuptake inhibitor
- Development stage
- Unknown
- Lead developer
- Helus Pharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous (SPL026), Oral (ssri)
01
Overview
**SPL026 + selective serotonin reuptake inhibitor** is a combination therapy consisting of SPL026 (a proprietary, pharmaceutical-grade formulation of intravenous N,N-dimethyltryptamine, or DMT) administered together with a selective serotonin reuptake inhibitor (SSRI), a class of antidepressants. SPL026 acts as a psychedelic agonist primarily at the serotonin 2A receptor, inducing rapid and intense psychedelic experiences. SSRIs block reuptake of serotonin via the serotonin transporter, leading to increased synaptic serotonin levels and gradual neurochemical changes. Recent clinical studies in patients with major depressive disorder (MDD) show that co-administration of SPL026 and SSRIs is safe and well-tolerated, with evidence of enhanced antidepressant efficacy compared to SPL026 alone. The developer is Small Pharma.
- Other names
- SPL026 + SSRISPL026 + selective serotonin reuptake inhibitor
02
Targets
HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on SPL026 + selective serotonin reuptake inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPL026 + selective serotonin reuptake inhibitor.